Moleculin Prices $9.3M Best-Efforts Offering at $0.75/Share — 90% Discount to Prior Close, Insiders Buy In
MBRX sits 88% above its 52-week low of $0.161 on elevated volume (3.9× avg).
Summary
Moleculin Biotech priced a $9.3 million best-efforts offering at $0.75 per share — a 90% discount to the prior close — with insiders buying $1.3M. The deal includes 37M warrants with a $0.75 strike and anti-dilution reset to $0.15, creating massive potential dilution as the company races to fund its pivotal AML trial.
Key Events · Financing and Capital Events · MBRX
-
Offering Priced at Deep Discount
11,088,334 shares + 37,130,001 common warrants at $0.75 combined price, plus 1,288,333 pre-funded warrants at $0.749 each, for total gross proceeds of ~$9.28M — a 90% discount to the $2.19 prior close.
-
Massive Warrant Overhang
37.1M common warrants with $0.75 exercise price and anti-dilution reset to $0.15 floor; if fully exercised, would add over 200% to the current 7.1M share float.
-
Insiders Commit $1.3M
Officers and directors agreed to purchase 1,319,998 shares + 3,959,994 common warrants on the same terms, signaling alignment but also the company's inability to raise funds without insider support.
-
Use of Proceeds: Clinical Development
Net proceeds of ~$8.5M will fund Annamycin's MIRACLE trial and working capital, extending runway into Q1 2027 per the prospectus.
Analysis · MBRX · Life Sciences
Moleculin Biotech priced a best-efforts public offering at $0.75 per share and accompanying warrants — a massive discount to the $2.19 prior close, reflecting extreme dilution and distress. The company, already under a going-concern warning and burning cash, is raising ~$8.5M net to fund its pivotal MIRACLE trial. Insiders are participating for $1.3M, but the offering structure — 11M shares plus 37M warrants with a $0.75 strike and anti-dilution reset to $0.15 — creates enormous overhang. If all warrants are exercised, dilution would exceed 200% of the current float. The deal follows a series of dilutive financings and comes just weeks after positive interim trial data, underscoring the company's desperate need for capital to reach the next data readout.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.1% of the 367 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.16 to $18.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.